Telitacicept for autoimmune nephropathy

Jingjing Cai; Dan Gao; Dan Gao; Dan Gao; Dan Gao; Dongwei Liu; Dongwei Liu; Dongwei Liu; Dongwei Liu; Zhangsuo Liu; Zhangsuo Liu; Zhangsuo Liu; Zhangsuo Liu

doi:10.3389/fimmu.2023.1169084

Frontiers in Immunology (Jun 2023)

Telitacicept for autoimmune nephropathy

Jingjing Cai,
Dan Gao,
Dan Gao,
Dan Gao,
Dan Gao,
Dongwei Liu,
Dongwei Liu,
Dongwei Liu,
Dongwei Liu,
Zhangsuo Liu,
Zhangsuo Liu,
Zhangsuo Liu,
Zhangsuo Liu

Affiliations

Jingjing Cai: Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Dan Gao: Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Dan Gao: Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China
Dan Gao: Henan Province Research Center for Kidney Disease, Zhengzhou, China
Dan Gao: Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
Dongwei Liu: Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Dongwei Liu: Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China
Dongwei Liu: Henan Province Research Center for Kidney Disease, Zhengzhou, China
Dongwei Liu: Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
Zhangsuo Liu: Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Zhangsuo Liu: Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China
Zhangsuo Liu: Henan Province Research Center for Kidney Disease, Zhengzhou, China
Zhangsuo Liu: Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China

DOI: https://doi.org/10.3389/fimmu.2023.1169084
Journal volume & issue: Vol. 14

Abstract

Read online

B cells and the humoral immunity are important players in the pathogenesis of autoimmune diseases. BAFF (also known as BLYS) and a proliferation-inducing ligand APRIL are required for the maintenance of the B-cell pool and humoral immunity. BAFF and APRIL can promote B-cell differentiation, maturation, and plasma cell antibody secretion. BAFF/APRIL overexpression has been identified in several autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, etc. Telitacicept, a novel fully human TACI-Fc fusion protein that binds both BAFF and APRIL, was approved in China in March 2021 for the treatment of systemic lupus erythematosus at a recommended dose of 160 mg/w subcutaneously and is in clinical trials for the treatment of multiple indications in other autoimmune diseases. In this review, we explored telitacicept’s mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords